• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Catinazzo Thomas sold $13,814 worth of shares (4,864 units at $2.84), decreasing direct ownership by 1% to 374,567 units (SEC Form 4)

    3/31/25 4:13:53 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RLAY alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Catinazzo Thomas

    (Last) (First) (Middle)
    C/O RELAY THERAPEUTICS, INC.
    399 BINNEY STREET, 2ND FLOOR

    (Street)
    CAMBRIDGE MA 02142

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Relay Therapeutics, Inc. [ RLAY ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/27/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/27/2025 S 298(1) D $2.84 379,133(2) D
    Common Stock 03/27/2025 S(3) 4,566 D $2.84 374,567(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
    2. Includes 254,354 shares underlying RSUs.
    3. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.
    /s/ Brian Adams, as Attorney-in-Fact 03/31/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RLAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLAY

    DatePrice TargetRatingAnalyst
    4/17/2025$4.00Equal Weight
    Wells Fargo
    9/10/2024$20.00Buy
    Goldman
    9/10/2024Outperform → Perform
    Oppenheimer
    9/10/2024$10.60 → $16.00Hold → Buy
    Jefferies
    5/10/2024$15.00Equal Weight → Overweight
    Barclays
    4/20/2023$12.50Underperform → Hold
    Jefferies
    4/19/2023$29.00Outperform → Strong Buy
    Raymond James
    4/13/2023$29.00Outperform
    Raymond James
    More analyst ratings

    $RLAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

      Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported

      5/5/25 4:05:18 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025. About Relay Therapeutics Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of bi

      4/28/25 4:05:39 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barbara Weber, M.D., Elected to ITM Supervisory Board

      Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM's Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (NASDAQ:TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK). ITM's Supervisory Board and the company overall will benefit from Dr. Weber's deep ex

      4/9/25 5:00:00 AM ET
      $BNTX
      $GSK
      $NVS
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RLAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Rahmer Peter sold $36,541 worth of shares (12,103 units at $3.02), decreasing direct ownership by 3% to 390,081 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      4/30/25 8:25:38 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Catinazzo Thomas sold $58,849 worth of shares (19,191 units at $3.07), decreasing direct ownership by 5% to 355,376 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      4/30/25 8:24:39 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President, R&D Bergstrom Donald A sold $95,381 worth of shares (31,562 units at $3.02), decreasing direct ownership by 5% to 583,490 units (SEC Form 4)

      4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

      4/30/25 8:24:14 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Relay Therapeutics Inc.

      SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      11/14/24 1:22:38 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Relay Therapeutics Inc. (Amendment)

      SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      2/14/24 4:20:24 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Relay Therapeutics Inc.

      SC 13G - Relay Therapeutics, Inc. (0001812364) (Subject)

      2/14/24 10:03:03 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Relay Therapeutics with a new price target

      Wells Fargo initiated coverage of Relay Therapeutics with a rating of Equal Weight and set a new price target of $4.00

      4/17/25 8:33:19 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman resumed coverage on Relay Therapeutics with a new price target

      Goldman resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $20.00

      9/10/24 7:59:04 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Relay Therapeutics from Outperform to Perform

      9/10/24 7:58:33 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Leadership Updates

    Live Leadership Updates

    See more

    $RLAY
    SEC Filings

    See more
    • Section 32 Raises $740 Million Venture Fund

      SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.

      11/4/21 8:14:00 AM ET
      $COIN
      $CRWD
      $EXAS
      $RLAY
      Finance: Consumer Services
      Finance
      Computer Software: Prepackaged Software
      Technology
    • Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

      Murcko brings over 30 years of chemistry development in biotech experience to the synthetic biology startup Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform. This press release

      10/14/21 8:00:00 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.

      CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointment of Patrick Riley, Ph.D., as senior vice president of artificial intelligence. Dr. Riley is an industry expert in artificial intelligence and machine learning, bringing 15 years of experience from Google and extensive knowledge in applying these technologies to drug discovery. Dr. Riley will lead a computational team and report to group head, Pat Walters. "We are excited to welcome Patrick to our computational organi

      5/10/21 6:00:00 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Relay Therapeutics Inc.

      10-Q - Relay Therapeutics, Inc. (0001812364) (Filer)

      5/5/25 4:15:17 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Relay Therapeutics, Inc. (0001812364) (Filer)

      5/5/25 4:10:07 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Relay Therapeutics Inc.

      SCHEDULE 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)

      4/30/25 11:12:24 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RLAY
    Financials

    Live finance-specific insights

    See more
    • Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

      New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a conference call today, December 11, at 7am ET (6am CT) SAN ANTONIO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and expe

      12/11/24 6:00:00 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

      CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows:Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3C

      12/9/24 4:05:30 PM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

      9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia Data support planned initiation of 2L pivotal study in 2025 Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with atirmociclib (CDK4) remains on track to start before year-end Relay Therapeutics to host a conference call today, September 9, at 8:00 a.m. ET CAMBRIDGE,

      9/9/24 6:55:20 AM ET
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care